0001628280-24-008979.txt : 20240305
0001628280-24-008979.hdr.sgml : 20240305
20240305165629
ACCESSION NUMBER: 0001628280-24-008979
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Konidaris Tasos
CENTRAL INDEX KEY: 0001320982
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38485
FILM NUMBER: 24721810
MAIL ADDRESS:
STREET 1: 103 JFK PARKWAY
CITY: SHORT HILLS
STATE: NJ
ZIP: 07078
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001723128
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
BUSINESS PHONE: (908) 947-3120
MAIL ADDRESS:
STREET 1: 400 CROSSING BOULEVARD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Holdings, Inc.
DATE OF NAME CHANGE: 20171117
4
1
wk-form4_1709675759.xml
FORM 4
X0508
4
2024-03-01
0
0001723128
Amneal Pharmaceuticals, Inc.
AMRX
0001320982
Konidaris Tasos
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
BRIDGEWATER
NJ
08807
0
1
0
0
Executive Vice President & CFO
0
Class A Common Stock
2024-03-01
4
M
0
36197
A
417037
D
Class A Common Stock
2024-03-01
4
F
0
13257
5.47
D
403780
D
Class A Common Stock
2024-03-03
4
M
0
45290
A
449070
D
Class A Common Stock
2024-03-03
4
F
0
15897
5.47
D
433173
D
Class A Common Stock
2024-03-03
4
M
0
57339
A
490512
D
Class A Common Stock
2024-03-03
4
F
0
20126
5.47
D
470386
D
Restricted Stock Units
2024-03-01
4
M
0
36197
0
D
Class A Common Stock
36197
36197
D
Restricted Stock Units
2024-03-03
4
M
0
45290
0
D
Class A Common Stock
45290
90580
D
Restricted Stock Units
2024-03-03
4
M
0
57339
0
D
Class A Common Stock
57339
172019
D
Restricted Stock Units
2024-03-04
4
A
0
175926
0
A
Class A Common Stock
175926
175926
D
Performance-Based Restricted Stock Units
2024-03-04
4
A
0
351852
0
A
Class A Common Stock
351852
351852
D
Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
The restricted stock units vest in four equal annual installments beginning on March 4, 2025.
Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Represents a performance-based restricted stock unit grant of 175,926 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period.
/s/ Denis Butkovic, Attorney-in-Fact
2024-03-05